Aripiprazole Lauroxil Patent Expiration
Aripiprazole Lauroxil is Used for managing symptoms of schizophrenia through various methods of administration. It was first introduced by Alkermes Inc
Aripiprazole Lauroxil Patents
Given below is the list of patents protecting Aripiprazole Lauroxil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aristada | US11273158 | Aripiprazole dosing strategy | Apr 06, 2039 | Alkermes Inc |
| Aristada Initio Kit | US11273158 | Aripiprazole dosing strategy | Apr 06, 2039 | Alkermes Inc |
| Aristada Initio Kit | US10016415 | Aripiprazole prodrug compositions | Sep 08, 2035 | Alkermes Inc |
| Aristada Initio Kit | US10688091 | Aripiprazole prodrug composition | Aug 17, 2035 | Alkermes Inc |
| Aristada Initio Kit | US10849894 | Aripiprazole prodrug composition | Aug 17, 2035 | Alkermes Inc |
| Aristada Initio Kit | US11154552 | Aripiprazole prodrug composition | Aug 17, 2035 | Alkermes Inc |
| Aristada | US10238651 | Aripiprazole formulations having increased injection speeds | Mar 19, 2035 | Alkermes Inc |
| Aristada | US10813928 | Aripiprazole formulations having increased injection speeds | Mar 19, 2035 | Alkermes Inc |
| Aristada | US11406632 | Aripiprazole formulations having increased injection speeds | Mar 19, 2035 | Alkermes Inc |
| Aristada | US9452131 | Aripiprazole formulations having increased injection speeds | Mar 19, 2035 | Alkermes Inc |
| Aristada | US9526726 | Aripiprazole formulations having increased injection speeds | Mar 19, 2035 | Alkermes Inc |
| Aristada | US11097006 | Pharmaceutical compositions having improved storage stability | Oct 24, 2033 | Alkermes Inc |
| Aristada | US9193685 | Pharmaceutical compositions having improved storage stability | Oct 24, 2033 | Alkermes Inc |
| Aristada | US9034867 | Pharmaceutical compositions comprising sorbitan esters | Nov 07, 2032 | Alkermes Inc |
| Aristada | US10226458 | Pharmaceutical compositions comprising sorbitan esters | Mar 19, 2032 | Alkermes Inc |
| Aristada | US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders | Oct 26, 2030 | Alkermes Inc |
| Aristada Initio Kit | US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders | Oct 26, 2030 | Alkermes Inc |
| Aristada | US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders | Jun 24, 2030 | Alkermes Inc |
| Aristada | US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders | Jun 24, 2030 | Alkermes Inc |
| Aristada Initio Kit | US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders | Jun 24, 2030 | Alkermes Inc |
| Aristada Initio Kit | US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders | Jun 24, 2030 | Alkermes Inc |
Aripiprazole Lauroxil's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List